Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Takeda Pharmaceutical Company Limited
< Previous
1
2
3
4
5
Next >
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
June 03, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
June 01, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
PFE
TAK
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
May 31, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
May 14, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
May 13, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
ACIU
TAK
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
May 09, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
April 26, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
April 18, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
April 08, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
March 26, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
March 26, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
March 19, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
March 13, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
February 26, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
February 12, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
February 08, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Chief Financial Officer Succession
February 01, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
February 01, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
January 29, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
January 29, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Named Global Top Employer for Seventh Consecutive Year
January 18, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
January 16, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
December 21, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
December 15, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners
December 05, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
November 27, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
November 09, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
November 08, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting
November 07, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance
October 26, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.